Verastem, Inc. (VSTM)
Chart Events
Performance Outlook
| Previous Close | 9.50 |
| Open | 9.56 |
| Bid | 9.60 x 1300 |
| Ask | 10.00 x 1000 |
| Day's Range | 9.30 - 9.83 |
| 52 Week Range | 3.48 - 15.12 |
| Volume | |
| Avg. Volume | 202,304 |
| Market Cap | 244.932M |
| Beta (5Y Monthly) | 0.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for VSTM
Related Research
- Verastem, Inc.Analyst Report: Incyte CorporationIncyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.RatingFair ValueEconomic Moat3 days agoMorningstar
- InvestorPlace
3 Penny Stocks That Can Triple Your Money in the Next 12 Months
When discussing penny stocks to buy, no one should be under any illusion: this sector presents extreme dangers. And it’s not just about the severity and acceleration of losses when getting things wrong. Rather, the red ink can also lead to significant psychological distress. You must not invest more than you can comfortably lose. At the same time, penny stocks don’t represent a monolith. Yes, the vast majority of ideas can be considered wildly risky. And even the ones that have legitimate upside
- Investor's Business Daily
Verastem Stock Is Outperforming 92% Of The Market — And It Just Surged
Verastem could be angling for an accelerated approval of its ovarian cancer treatment, an analyst said Thursday as she upgraded VSTM stock.
- Simply Wall St.
Strong week for Verastem (NASDAQ:VSTM) shareholders doesn't alleviate pain of five-year loss
It's nice to see the Verastem, Inc. ( NASDAQ:VSTM ) share price up 15% in a week. But will that repair the damage for...
